Cargando…
Peripheralized sepiapterin reductase inhibition as a safe analgesic therapy
The development of novel analgesics for chronic pain in the last 2 decades has proven virtually intractable, typically failing due to lack of efficacy and dose-limiting side effects. Identified through unbiased gene expression profiling experiments in rats and confirmed by human genome-wide associat...
Autores principales: | Cronin, Shane J. F., Andrews, Nick A., Latremoliere, Alban |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213231/ https://www.ncbi.nlm.nih.gov/pubmed/37251335 http://dx.doi.org/10.3389/fphar.2023.1173599 |
Ejemplares similares
-
Sepiapterin reductase: Characteristics and role in diseases
por: Wu, Yao, et al.
Publicado: (2020) -
Repurposing of Tranilast for Potential Neuropathic
Pain Treatment by Inhibition of Sepiapterin Reductase in the BH(4) Pathway
por: Moore, Benjamin J. R., et al.
Publicado: (2019) -
Sepiapterin reductase gene‐disrupted mice suffer from hypertension with fluctuation and bradycardia
por: Sumi‐Ichinose, Chiho, et al.
Publicado: (2017) -
Leaky splicing variant in sepiapterin reductase deficiency: Are milder cases escaping diagnosis?
por: Nakagama, Yu, et al.
Publicado: (2019) -
Evaluation of the silkworm lemon mutant as an invertebrate animal model for human sepiapterin reductase deficiency
por: Jiang, Guihua, et al.
Publicado: (2020)